Transcripta Bio employs advanced technologies to revolutionize drug discovery through a comprehensive understanding of gene expression and molecular interactions. Central to their approach is the Drug-Gene Atlas, which serves as a premier discovery engine that maps the relationship between molecular structures and drug actions across the entire cell transcriptome. This extensive mapping enables the identification of therapeutic candidates that can effectively rebalance gene expression to combat various diseases. Additionally, the company utilizes its proprietary Conductor AI modeling suite to predict gene responses to billions of novel compounds, facilitating the rapid synthesis and testing of new drug candidates in their laboratory.

The company’s innovative methodology allows for a significantly accelerated drug discovery process, achieving results 2-5 years faster than traditional methods. Transcripta Bio screens thousands of molecules against 20,000 genes, providing a high-throughput analysis that characterizes the effects of over 800,000 data points for each compound. This rigorous approach not only ensures 100% target certainty backed by genetic evidence but also identifies root cause genes that can lead to expedited clinical pathways. By virtually screening billions of compounds and synthesizing promising candidates, Transcripta Bio is positioned to make substantial contributions to the field of therapeutics, ultimately aiming to enhance human health through impactful innovations.

United States

We are focused on drug discovery at unprecedented speed and scale, with lower risk and higher certainty across multiple diseases in parallel.

With data from hundreds of millions of experiments, we have mapped the effects of thousands of compounds on gene expression to discover new therapies. Our Drug-Gene Atlas maps molecular structure and drug action to the whole cell transcriptome, revealing therapeutic candidates that rebalance gene expression to treat disease. Our proprietary artificial intelligence modeling suite, Conductor AI, used our Drug-Gene Atlas to discover and predict the effects of new drugs at transcriptome scale.

Transcripta Bio

Company Details